Protagonist Reports 2-Year Follow Up Data From Rusfertide REVIVE Study at the ASH Annual Meeting
Protagonist Reports 2-Year Follow Up Data From Rusfertide REVIVE Study at the ASH Annual Meeting
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two-year follow up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera (PV) and other disease indications. Copies of the presentations will be available on the Events and Presentations section of the Protagonist website.
Proganist Therapeutics, Inc.（“主角” 或 “公司”）在美国血液学会2023年年会上公布了五份摘要的详细信息，其中包括一份口头陈述，其中附有使用rusfertide的2期REVIVE研究的为期两年的随访数据，Rusfertide是一种模拟天然激素hepcidin的模拟物，在治疗真性红细胞增多症（PV）和其他疾病适应症方面具有潜在的治疗价值。演示文稿的副本将在主角网站的 “活动和演示” 部分提供。
译文内容由第三方软件翻译。